



Changes to the Laboratory National Coverage Determination Edit Software: January 2024 Update

Related CR Release Date: August 24, 2023

MLN Matters Number: MM13350

Effective Date: January 1, 2024

Related Change Request (CR) Number: [CR 13350](#)

Implementation Date: January 2, 2024

Related CR Transmittal Number: R12119CP

Related CR Title: Changes to the Laboratory National Coverage Determination (NCD) Edit Software for January 2024

Affected Providers

- Physicians
- Suppliers
- Other providers billing Medicare Administrative Contractors (MACs) for services they provide to Medicare patients

Action Needed

Make sure your billing staffs know about:

- Newly available codes
- Recent coding changes
- How to find NCD coding information

Background

The purpose of this Change Request (CR) is to announce the changes that will be included in the January 2024 quarterly release of the edit module for clinical diagnostic laboratory services.

The National Coverage Determinations (NCDs) for clinical diagnostic laboratory services were developed by the laboratory negotiated rulemaking committee, and the final rule was published on November 23, 2001. Nationally uniform software was developed and incorporated in the Medicare shared systems so that laboratory claims subject to one of the 23 NCDs (Publication 100-03, Sections 190.12 - 190.34) were processed uniformly throughout the nation, effective April 1, 2003. Relevant Laboratory NCD coding changes in CR 13350 include:

- NCD 190.12 – Urine Culture, Bacterial
- NCD 190.13 – Human Immunodeficiency Virus (HIV) Testing (Prognosis Including Monitoring)

- NCD 190.14 – Human Immunodeficiency Virus (HIV) Testing (Diagnosis)
- NCD 190.15 – Blood Counts
- NCD 190.16 – Partial Thromboplastin Time (PTT)
- NCD 190.17 – Prothrombin Time (PT)
- NCD 190.18 – Serum Iron Studies
- NCD 190.19 – Collagen Crosslinks, Any Method
- NCD 190.20A – Blood Glucose Testing
- NCD 190.20B – Blood Glucose Testing
- NCD 190.21 – Glycated Hemoglobin/Glycated Protein
- NCD 190.22 – Thyroid Testing
- NCD 190.23A – Lipids Testing
- NCD 190.23B – Lipids Testing
- NCD 190.24 – Digoxin Therapeutic Drug Assay
- NCD 190.25 – Alpha-fetoprotein
- NCD 190.26 – Carcinoembryonic Antigen
- NCD 190.27 – Human Chorionic Gonadotropin
- NCD 190.28 – Tumor Antigen by Immunoassay CA 125
- NCD 190.29 – Tumor Antigen by Immunoassay CA 15-3/CA 27.29
- NCD 190.30 – Tumor Antigen by Immunoassay CA 19-9
- NCD 190.31 – Prostate Specific Antigen
- NCD 190.32 – Gamma Glutamyl Transferase
- NCD 190.33 – Hepatitis Panel/Acute Hepatitis Panel
- NCD 190.34 – Fecal Occult Blood Test

[Previous NCD coding changes](#) are available. Also, see the [NCD spreadsheets](#) for CR 13350.

CMS isn't including any policy changes in this ICD-10 quarterly update. We cover NCD policy changes using the current, longstanding NCD process.

Your MAC will adjust any claims processed in error associated with CR 13350 that you bring to their attention.

More Information

We issued CR 13350 to your MAC as the official instruction for this change.

For more information, [find your MAC's website](#).

Document History

Date of Change	Description
August 28, 2023	Initial article released.

View the [Medicare Learning Network® Content Disclaimer and Department of Health & Human Services Disclosure](#).

The Medicare Learning Network®, MLN Connects®, and MLN Matters® are registered trademarks of the U.S. Department of Health & Human Services (HHS).